+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Efficacy of melaleuca oral solution for the treatment of fluconazole refractory oral candidiasis in AIDS patients



Efficacy of melaleuca oral solution for the treatment of fluconazole refractory oral candidiasis in AIDS patients



Aids 12(9): 1033-1037



Objective: To evaluate the efficacy of melaleuca oral solution in AIDS patients with fluconazole-resistant oropharyngeal candida infections. Design: A prospective, single center, open-labeled study. Setting: A university-based inner-city HIV/AIDS clinic. Patients: Thirteen patients with AIDS and oral candidiasis documented to be clinically refractory to fluconazole, as defined by failure to respond to a minimum of 14 days of gtoreq 400 mg fluconazole per day. Additionally, patients had in vitro resistance to fluconazole, defined by minimal inhibitory concentrations of gtoreq 20 mug/ml. Interventions: Patients were given 15 ml melaleuca oral solution four times daily to swish and expel for 2-4 weeks. Main outcome measures: Resolution of clinical lesions of oral pseudomembranous candidiasis lesions. Evaluations were performed weekly for 4 weeks and at the end of therapy for clinical signs of oral candidiasis. Quantitative yeast cultures were performed at each evaluation. Results: A total of 13 patients were entered into the study, 12 were evaluable. At the 2-week evaluation, seven out of 12 patients had improved, none were cured, and six were unchanged. At the 4-week evaluation, eight out of 12 patients showed a response (two cured, six improved), four were non-responders, and one had deteriorated. A mycological response was seen in seven out of 12 patients. A followup evaluation 2-4 weeks after therapy was discontinued revealed that there were no clinical relapses in the two patients who were cured. Conclusions: Melaleuca oral solution appears to be effective as an alternative regimen for AIDS patients with oropharyngeal candidiasis refractory to fluconazole.

(PDF emailed within 0-6 h: $19.90)

Accession: 003122915

Download citation: RISBibTeXText

PMID: 9662200

DOI: 10.1097/00002030-199809000-00011


Related references

Efficacy of Alcohol-Based and Alcohol-Free Melaleuca Oral Solution for the Treatment of Fluconazole-Refractory Oropharyngeal Candidiasis in Patients with Aids. Hiv Clinical Trials 3(5): 379-385, 2002

Efficacy of alcohol-based and alcohol-free melaleuca oral solution for the treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS. HIV Clinical Trials 3(5): 379-385, 2002

Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. Aids Research and Human Retroviruses 15(16): 1413-1417, 1999

A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clinical Infectious Diseases 26(6): 1368-1373, 1998

A Double-Blind Comparison of Itraconazole Oral Solution and Fluconazole Capsules for the Treatment of Oropharyngeal Candidiasis in Patients with Aids. Clinical Infectious Diseases 26(6): 1368-1373, 1998

Efficacy of oral fluconazole in the treatment of AIDS associated oesophageal candidiasis. European Journal of Clinical Microbiology and Infectious Diseases 10(6): 503-505, 1991

Comparison of itraconazole oral solution and fluconazole capsules in the treatment of oral and esophageal candidiasis in hiv infected patients preliminary results. Istituto Superiore Di Sanita Vii International Conference on Aids: Science Challenging Aids; Florence, Italy, June 16-21, 464p (Vol 1); 460p (Vol 2) Istituto Superiore Di Sanita: Rome, Italy Paper : 232, 1991

Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295. Aids 14(7): 845-852, 2000

Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in aids patients. Brazilian Journal of Infectious Diseases 5(2): 60-66, 2001

Randomized study of fluconazole oral solution versus amphotericin B oral solution in oropharyngeal candidiasis in elderly patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 490, 1998

Fluconazole in the treatment of esophageal, bronchial and oral candidiasis in patients with ARC and AIDS. Giornale Italiano di Chemioterapia 35(1-3): 61-68, 1988

Fluconazole and ketoconazole in the treatment of oral and esophageal candidiasis in AIDS patients. Journal of ChemoTherapy 4(6): 381-386, 1992

Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. Journal of Clinical Microbiology 32(1): 59-64, 1994

Efficacy of fluconazole and itraconazole in the treatment of oral candidiasis in HIV patients. Acta Tropica 80(2): 151-154, 2001

Comparative clinical study of oral suspension fluconazole versus topical liquid oral nystatin in the treatment of oropharyngeal candidiasis in AIDS. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 35(0): 244, 1995